The clinical coherence of Glow rests on three synergistic relationships between its actives:

Tretinoin + Estriol create dual-pathway collagen support — tretinoin via RAR-mediated transcriptional upregulation of collagen genes and MMP inhibition; estriol via estrogen receptor activation of procollagen synthesis and independent MMP-1 suppression. Two receptor systems, one structural outcome. Estriol additionally restores the skin environment — thickness, hydration, receptor density — that optimizes cellular response to tretinoin's signals.

Tretinoin + Niacinamide form the tolerability partnership at the heart of this formula. Tretinoin drives accelerated cellular turnover and collagen remodeling; niacinamide repairs the barrier disruption and dampens the inflammatory response that this acceleration can trigger. The result is that patients can maintain consistent nightly tretinoin use — which is required for clinical efficacy — without the irritation-driven discontinuation that limits outcomes when tretinoin is used alone.

Estriol + Niacinamide contribute complementary hydration support — estriol increasing endogenous hyaluronic acid synthesis in the dermis, niacinamide reinforcing the stratum corneum lipid matrix that retains that moisture at the surface. Together they sustain both deep dermal hydration and surface barrier integrity, addressing moisture loss at both the production and retention levels.

All three actives contribute independently to pigmentation correction through distinct mechanisms — tretinoin normalizing melanocyte activity, niacinamide inhibiting melanosome transfer, estriol reducing the inflammatory signals that drive post-inflammatory hyperpigmentation — making Glow a particularly effective formulation for uneven skin tone and sunspot reduction.

With consistent nightly use as part of a supervised skincare protocol, Glow supports:

Reduction in the appearance of fine lines and improvement in wrinkle depth and structure

Improved skin firmness, elasticity, and dermal thickness

Accelerated, well-tolerated epidermal cell turnover with reduced retinoid irritation

Increased dermal collagen density through dual-pathway stimulation

Reduction of hyperpigmentation, sunspots, and uneven skin tone through three complementary mechanisms

Reversal of estrogen-related skin thinning, dryness, and laxity

Strengthened skin barrier with reduced transepidermal water loss

Refined pore appearance and reduced sebum overactivity

Reduced surface redness and inflammation — particularly valuable in rosacea-prone or reactive skin

Supported cellular energy metabolism and DNA repair via niacinamide's NAD+ precursor activity

A radiant, even-toned, and progressively more youthful-appearing complexion

Results vary by individual. Hydration improvement and reduced redness are typically noticed within the first 2–4 weeks. Meaningful collagen remodeling, wrinkle reduction, and pigmentation correction develop over 8–12 weeks of consistent use, with continued improvement through 6 months.

Glow is for evening / bedtime use only. Tretinoin is photolabile and increases photosensitivity; daytime application reduces efficacy and increases sunburn risk. Always apply at night.

Application Instructions:

Cleanse the face thoroughly and pat completely dry. Allow skin to dry for 10–15 minutes before applying — tretinoin-containing products applied to damp skin penetrate more aggressively and increase irritation risk during the adjustment period.

Dispense a small amount (a pea-sized quantity covers the full face) onto fingertips.

Apply in a thin, even layer to the face and neck, avoiding the immediate eye area, corners of the nose, and lip margins.

Allow to absorb fully before applying any other products. A gentle moisturizer may be layered on top if additional hydration is desired.

Wash hands thoroughly after application.

Starting Protocol — Retinoid Adjustment Period: Despite niacinamide's tolerability-enhancing properties, some patients — particularly those new to retinoids — may experience mild redness or flaking during the first 2–4 weeks. This is the expected retinoid adjustment phase, not an allergic reaction. To minimize initial irritation:

Begin with every-other-night application for the first 1–2 weeks, then advance to nightly as tolerated.

Ensure a gentle, fragrance-free morning moisturizer and daily SPF are applied consistently.

Avoid other exfoliating actives during the initial adjustment period unless directed by your provider.

Glow's niacinamide content means the adjustment period is typically milder and shorter than with tretinoin-only preparations. Many patients tolerate nightly use from the outset, but a gradual start is always prudent.

Morning Routine Requirement: Daily broad-spectrum sunscreen (SPF 30 or higher) is mandatory during tretinoin therapy. Unprotected sun exposure during active tretinoin use significantly increases the risk of sunburn, irritation, and paradoxical hyperpigmentation. This is not optional.

This is a prescription-only compounded medication containing tretinoin, a teratogenic retinoid. Patients must be counseled before initiating therapy.

Contraindications:

Pregnancy: Tretinoin is teratogenic — it causes birth defects when absorbed systemically. While systemic absorption from topical facial tretinoin at standard concentrations is very low, it is not zero. Glow is contraindicated during pregnancy. Women of reproductive age should use reliable contraception during treatment and discontinue immediately if pregnancy occurs or is planned.

Breastfeeding: Safety of topical tretinoin and estriol during lactation has not been established. Use is not recommended.

Hormone-sensitive malignancies: Estriol is an estrogen. Patients with a personal history of estrogen receptor-positive breast cancer, endometrial cancer, or other hormone-sensitive conditions should discuss use explicitly with their oncologist or treating physician before initiating therapy.

Active inflammatory skin conditions: Glow should not be applied to actively inflamed, broken, sunburned, or acutely irritated skin. Niacinamide's anti-inflammatory properties offer some additional tolerance, but active skin compromise remains a contraindication to tretinoin initiation.

Known component sensitivity: Patients with documented sensitivity to retinoids, niacinamide, or estriol should not use this product.

Potential Side Effects:

Tretinoin-related (most common early in treatment):

Mild redness, peeling, or dryness during the retinoid adjustment period — expected and transient, and typically less pronounced in Glow than in tretinoin-only preparations due to niacinamide co-formulation

Increased photosensitivity — managed by mandatory daily SPF

Temporary skin sensitivity to wind, cold, and environmental factors

Niacinamide-related:

Niacinamide is exceptionally well tolerated; isolated sensitivity reactions are rare

At high concentrations (above those typically used in compounded formulas), niacinamide can theoretically convert to nicotinic acid and cause transient flushing — not expected at standard compounding concentrations

Estriol-related:

Mild local skin sensitivity in patients with very reactive skin

Rare reports of mild systemic estrogenic effects (breast tenderness) at significant systemic absorption — uncommon at low topical facial concentrations

General:

Contact dermatitis in patients with allergy to any formula component

Worsening photosensitivity — managed by strict SPF adherence

Seek provider evaluation if you experience: persistent severe irritation beyond the expected adjustment period, spreading rash or blistering, unexpected systemic symptoms, or signs of pregnancy.

Other topical retinoids (adapalene, tazarotene, retinol): Concurrent use with other retinoid-class products significantly increases irritation risk without proportional benefit. Do not combine without explicit provider direction.

Topical exfoliating acids (AHAs/BHAs) and benzoyl peroxide: Benzoyl peroxide inactivates tretinoin on contact. AHAs and BHAs increase barrier disruption risk when combined with tretinoin. Avoid concurrent use, particularly during the retinoid adjustment period.

Vitamin C (ascorbic acid) serums: Niacinamide and vitamin C have historically been described as incompatible due to the risk of forming a nicotinic acid-niacin complex. At concentrations and temperatures typical of topical formulations, this conversion is clinically negligible and unlikely to cause meaningful irritation — but patients who experience unexpected flushing when layering a vitamin C serum over Glow should separate application timing or discuss with their provider.

Photosensitizing medications: Certain antibiotics, diuretics, and antifungals increase photosensitivity additively with tretinoin. Strict daily sun protection is essential throughout therapy.

Oral hormonal therapies: Patients on menopausal hormone therapy, oral contraceptives, or other estrogen-modulating treatments should ensure all prescribing providers are aware of the topical estriol component of this formulation.

Store at room temperature, 68°F – 77°F (20°C – 25°C), away from direct heat, humidity, and light

Keep container tightly closed

Do not freeze

Tretinoin is light-sensitive — store in original packaging, away from sunlight

Keep out of reach of children

Use before the labeled expiration date